Jude Onyia - 29 Nov 2021 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Scientific Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
29 Nov 2021
Net transactions value
$0
Form type
4
Filing time
01 Dec 2021, 19:02:14 UTC
Next filing
02 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Stock Option Award $0 +120,169 $0.000000 120,169 29 Nov 2021 Common Stock 120,169 $84.74 Direct F1
transaction NBIX Restricted Stock Unit Award $0 +17,702 $0.000000 17,702 29 Nov 2021 Common Stock 17,702 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
F3 The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025.